A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 107, Issue 3, 2007, Pages 586-589

  Carter, Jori ^a   Durfee, John ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bowel perforation; Epithelial ovarian cancer; Gastrointestinal perforation; Neoadjuvant chemotherapy

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; AGED; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL EXAMINATION; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE PERFORATION; OVARY CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTESTINAL PERFORATION; NECROSIS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 36448989327     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.09.008     Document Type: Article

References (27)

1. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (1998) 103-108
2. Hoskins W.J. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 55 (1994) S91-S96
3. Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J., Mathevet P., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter trial. Cancer 91 12 (2001) 2329-2334
4. Vergote I.B., De Wever I., Decloedt J., Tjalma W., van Gramberen M., and van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 27 3, Suppl 7 (2000) 31-36
5. Chen H.X., Mooney M., Boron M., Vena D., Mosby K., Grochow L., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24 21 (2006) 3354-3360
6. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 suppl 3 (2005) 25-33
7. Hurwitz H., Fehrenbacher L., Novonty W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEJM 350 23 (2004) 2335-2342
8. Wright J.D., Hagemann A., Rader J.S., Viviano D., Gibb R.K., Norris L., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107 1 (2006) 83-89
9. Hande K.R., Fisher R.I., DeVita V.T., Chabner B.A., and Yound R.C. Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer 41 (1978) 1984-1989
10. Kluin-Nelemans H.C., Zagonel V., Anastasopoulou A., Bron D., Roozendaal K.J., Noordijk E.M., et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: a randomized phase III EORTC study. J Natl Cancer Inst 93 1 (2001) 22-30
11. Torosian M.H., and Turnbull A.D.M. Emergency laparotomy for spontaneous intestinal and colonic perforations in cancer patients receiving corticosteroids and chemotherapy. J Clin Oncol 6 2 (1988) 291-296
12. Vose J.M., Link M.L., Grossbard M., Czuczman A., Grillo-Lopez P., Gilman A.L., et al. Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19 2 (2001) 389-397
13. Hruban R.H., Yardly J.H., Donehower R.C., and Boitnott J.K. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63 (1989) 1944-1950
14. Rose P.G., and Piver M.S. Intestinal perforation secondary to paclitaxel. Gynecol Oncol 57 (1995) 270-272
15. Seewaldt V.L., Greer B.E., Cain J.M., Figge D.C., Tamimi H.K., Brown W.S., et al. Paclitaxol (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 170 6 (1994) 1666-1671
16. Seewaldt V.L., Cain J.M., Goff B.A., Tamimi H., Greer B., and Figge D. A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol 67 (1997) 137-140
17. Han E.S., and Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gyecol Oncol 105 (2007) 3-6
18. Warshaw A.L., Welch J.P., and Ottinger L.W. Acute perforation of the colon associated with chronic corticosteroid therapy. Am J Surgery 131 (1976) 442-446
19. Remine S.G., and McIlrath D.C. Bowel perforation in steroid-treated patients. Ann Surg 192 4 (1980) 581-586
20. Kuhn W., Rutke S., Spathe K., Schmalfeldt B., Florack G., von Hundelshausen B., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 92 10 (2001) 2585-2591
21. Lee S.J., Kim B.G., Lee J.W., Park C.S., Lee J.H., and Bae D.S. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res 32 1 (2006) 99-106
22. Mazzeo F., Berliere M., Kerger J., Squifflet J., Duck L., D'Hondt V., et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90 (2003) 163-169
23. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., and Thiel R.P. Neodjuvant chemotherapy for advanced ovarian cancer: long term survival. Gynecol Oncol 72 (1999) 93-99
24. Jacob J.H., Gershenson D.M., Morris M., Copeland L.J., Burke T.W., and Wharton T. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 42 (1991) 146-150
25. Hou J.Y., Kelly M.G., Yu H., McAlpine J.N., Azodi M., Rutherford T.J., et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian epithelial cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105 (2007) 211-217
26. Bristow R.E., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103 (2006) 1070-1076
27. Han E.S., and Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol Oncol 105 (2007) 3-6